Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00265551 | Study Evaluating SCA-136 in Subjects With Acute Exacerbations of Schizophrenia | PHASE2 | COMPLETED | 300 | — | — | Jan 1, 2006 | Jan 1, 2007 | Dec 10, 2007 | 35 | United States |
| NCT00505973 | Study Evaluating the Safety and Tolerability of SCA-136 in Healthy Japanese Male Subjects | PHASE1 | COMPLETED | 24 | — | — | Jul 1, 2007 | Oct 1, 2007 | Dec 5, 2007 | 1 | Japan |
| NCT00458107 | Study Evaluating the Safety and Tolerability of SCA-136 in Healthy Japanese and Non-Japanese Female Subjects | PHASE1 | COMPLETED | 64 | — | — | Apr 1, 2007 | Sep 1, 2007 | Dec 5, 2007 | 1 | United States |
| NCT00447941 | Safety, PK and PD Study in Healthy Male Japanese Subjects | PHASE1 | COMPLETED | 24 | — | — | Jun 1, 2006 | Aug 1, 2006 | Aug 7, 2009 | - | — |
| Name | Type | Description |
|---|---|---|
| SCA-136 (200 mg) | DRUG | - |
| SCA-136 (400 mg) | DRUG | - |
| olanzapine (15 mg) | DRUG | - |
| placebo | DRUG | - |
| SCA-136 | DRUG | - |
Inclusion Criteria: * Clinical diagnosis of schizophrenia * Ability to remain hospitalized for at least first 4 weeks of study * Needs hospitalization due to worsening of schizophrenia Exclusion Criteria: * Type 1 or 2 diabetes * Previous use of clozapine * Serious medical illness other than schi...